nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferiprone—Hypersplenism—Hydroxyurea—head and neck cancer	0.193	0.236	CcSEcCtD
Deferiprone—Effusion—Docetaxel—head and neck cancer	0.0458	0.0559	CcSEcCtD
Deferiprone—Cerebellar syndrome—Fluorouracil—head and neck cancer	0.0332	0.0405	CcSEcCtD
Deferiprone—Fibrosis—Hydroxyurea—head and neck cancer	0.0324	0.0395	CcSEcCtD
Deferiprone—Fibrosis—Fluorouracil—head and neck cancer	0.0233	0.0284	CcSEcCtD
Deferiprone—UGT1A6—Estrogen metabolism—GSTM1—head and neck cancer	0.0229	0.127	CbGpPWpGaD
Deferiprone—UGT1A6—Estrogen metabolism—CYP1A1—head and neck cancer	0.0217	0.12	CbGpPWpGaD
Deferiprone—Acute respiratory distress syndrome—Docetaxel—head and neck cancer	0.0184	0.0225	CcSEcCtD
Deferiprone—Enterocolitis—Docetaxel—head and neck cancer	0.0173	0.0211	CcSEcCtD
Deferiprone—Gastrointestinal symptom NOS—Hydroxyurea—head and neck cancer	0.0157	0.0192	CcSEcCtD
Deferiprone—UGT1A6—Oxidative Stress—SOD2—head and neck cancer	0.0153	0.0848	CbGpPWpGaD
Deferiprone—Multi-organ failure—Docetaxel—head and neck cancer	0.0147	0.018	CcSEcCtD
Deferiprone—UGT1A6—Oxidative Stress—GPX1—head and neck cancer	0.0146	0.0809	CbGpPWpGaD
Deferiprone—UGT1A6—Oxidative Stress—CYP1A1—head and neck cancer	0.0144	0.08	CbGpPWpGaD
Deferiprone—Nystagmus—Vinblastine—head and neck cancer	0.0142	0.0173	CcSEcCtD
Deferiprone—UGT1A6—Phase II conjugation—NAT2—head and neck cancer	0.013	0.0723	CbGpPWpGaD
Deferiprone—Gastrointestinal symptom NOS—Fluorouracil—head and neck cancer	0.0113	0.0138	CcSEcCtD
Deferiprone—Rectal haemorrhage—Vinblastine—head and neck cancer	0.0112	0.0137	CcSEcCtD
Deferiprone—UGT1A6—Aryl Hydrocarbon Receptor Pathway—CYP1A1—head and neck cancer	0.0103	0.0569	CbGpPWpGaD
Deferiprone—Nystagmus—Fluorouracil—head and neck cancer	0.00932	0.0114	CcSEcCtD
Deferiprone—UGT1A6—Biological oxidations—NAT2—head and neck cancer	0.00763	0.0423	CbGpPWpGaD
Deferiprone—UGT1A6—Metapathway biotransformation—NAT2—head and neck cancer	0.00752	0.0417	CbGpPWpGaD
Deferiprone—UGT1A6—NRF2 pathway—TGFA—head and neck cancer	0.00739	0.041	CbGpPWpGaD
Deferiprone—UGT1A6—Phase II conjugation—GSTM1—head and neck cancer	0.00644	0.0357	CbGpPWpGaD
Deferiprone—Pancytopenia—Vinblastine—head and neck cancer	0.00604	0.00737	CcSEcCtD
Deferiprone—Sepsis—Fluorouracil—head and neck cancer	0.00578	0.00705	CcSEcCtD
Deferiprone—Pancreatitis—Hydroxyurea—head and neck cancer	0.00569	0.00694	CcSEcCtD
Deferiprone—UGT1A6—Aryl Hydrocarbon Receptor Pathway—IL2—head and neck cancer	0.00565	0.0313	CbGpPWpGaD
Deferiprone—Pancytopenia—Hydroxyurea—head and neck cancer	0.00551	0.00672	CcSEcCtD
Deferiprone—Neutropenia—Hydroxyurea—head and neck cancer	0.00542	0.00662	CcSEcCtD
Deferiprone—Agranulocytosis—Vinblastine—head and neck cancer	0.00529	0.00646	CcSEcCtD
Deferiprone—Weight increased—Hydroxyurea—head and neck cancer	0.00528	0.00644	CcSEcCtD
Deferiprone—Infestation NOS—Hydroxyurea—head and neck cancer	0.00517	0.00631	CcSEcCtD
Deferiprone—Infestation—Hydroxyurea—head and neck cancer	0.00517	0.00631	CcSEcCtD
Deferiprone—Blood bilirubin increased—Docetaxel—head and neck cancer	0.00508	0.0062	CcSEcCtD
Deferiprone—Pharyngitis—Vinblastine—head and neck cancer	0.00505	0.00617	CcSEcCtD
Deferiprone—Cardiac failure—Fluorouracil—head and neck cancer	0.00495	0.00604	CcSEcCtD
Deferiprone—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00489	0.00597	CcSEcCtD
Deferiprone—Osteoarthritis—Fluorouracil—head and neck cancer	0.00483	0.00589	CcSEcCtD
Deferiprone—Pulmonary embolism—Docetaxel—head and neck cancer	0.0048	0.00586	CcSEcCtD
Deferiprone—UGT1A6—Aryl Hydrocarbon Receptor Pathway—EGFR—head and neck cancer	0.00432	0.024	CbGpPWpGaD
Deferiprone—UGT1A6—NRF2 pathway—GSTM1—head and neck cancer	0.0043	0.0238	CbGpPWpGaD
Deferiprone—Angiopathy—Hydroxyurea—head and neck cancer	0.00421	0.00514	CcSEcCtD
Deferiprone—Sepsis—Docetaxel—head and neck cancer	0.00417	0.00509	CcSEcCtD
Deferiprone—Chills—Hydroxyurea—head and neck cancer	0.00417	0.00508	CcSEcCtD
Deferiprone—Pancytopenia—Fluorouracil—head and neck cancer	0.00397	0.00484	CcSEcCtD
Deferiprone—Convulsion—Vinblastine—head and neck cancer	0.00384	0.00469	CcSEcCtD
Deferiprone—Hypertension—Vinblastine—head and neck cancer	0.00383	0.00467	CcSEcCtD
Deferiprone—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.00381	0.00465	CcSEcCtD
Deferiprone—UGT1A6—Biological oxidations—GSTM1—head and neck cancer	0.00377	0.0209	CbGpPWpGaD
Deferiprone—Pneumonia—Fluorouracil—head and neck cancer	0.00374	0.00457	CcSEcCtD
Deferiprone—Discomfort—Vinblastine—head and neck cancer	0.00373	0.00455	CcSEcCtD
Deferiprone—Infestation NOS—Fluorouracil—head and neck cancer	0.00372	0.00454	CcSEcCtD
Deferiprone—Infestation—Fluorouracil—head and neck cancer	0.00372	0.00454	CcSEcCtD
Deferiprone—UGT1A6—Metapathway biotransformation—GSTM1—head and neck cancer	0.00372	0.0206	CbGpPWpGaD
Deferiprone—Atrial fibrillation—Docetaxel—head and neck cancer	0.00368	0.00449	CcSEcCtD
Deferiprone—Cardiac failure—Docetaxel—head and neck cancer	0.00357	0.00436	CcSEcCtD
Deferiprone—UGT1A6—Biological oxidations—CYP1A1—head and neck cancer	0.00357	0.0198	CbGpPWpGaD
Deferiprone—UGT1A6—Metapathway biotransformation—CYP1A1—head and neck cancer	0.00352	0.0195	CbGpPWpGaD
Deferiprone—Epistaxis—Fluorouracil—head and neck cancer	0.00351	0.00428	CcSEcCtD
Deferiprone—Convulsion—Hydroxyurea—head and neck cancer	0.0035	0.00427	CcSEcCtD
Deferiprone—Pain in extremity—Docetaxel—head and neck cancer	0.00349	0.00425	CcSEcCtD
Deferiprone—Agranulocytosis—Fluorouracil—head and neck cancer	0.00347	0.00424	CcSEcCtD
Deferiprone—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00342	0.00417	CcSEcCtD
Deferiprone—Discomfort—Hydroxyurea—head and neck cancer	0.0034	0.00415	CcSEcCtD
Deferiprone—Pharyngitis—Fluorouracil—head and neck cancer	0.00332	0.00405	CcSEcCtD
Deferiprone—Infection—Hydroxyurea—head and neck cancer	0.00328	0.004	CcSEcCtD
Deferiprone—Dehydration—Docetaxel—head and neck cancer	0.00324	0.00396	CcSEcCtD
Deferiprone—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00323	0.00395	CcSEcCtD
Deferiprone—Skin disorder—Hydroxyurea—head and neck cancer	0.0032	0.00391	CcSEcCtD
Deferiprone—Decreased appetite—Vinblastine—head and neck cancer	0.00314	0.00384	CcSEcCtD
Deferiprone—UGT1A6—Metabolism—UROD—head and neck cancer	0.00314	0.0174	CbGpPWpGaD
Deferiprone—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.00314	0.00383	CcSEcCtD
Deferiprone—Pain—Vinblastine—head and neck cancer	0.00309	0.00377	CcSEcCtD
Deferiprone—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.00308	0.00375	CcSEcCtD
Deferiprone—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00296	0.00361	CcSEcCtD
Deferiprone—Somnolence—Hydroxyurea—head and neck cancer	0.00293	0.00358	CcSEcCtD
Deferiprone—Dyspepsia—Hydroxyurea—head and neck cancer	0.0029	0.00354	CcSEcCtD
Deferiprone—Decreased appetite—Hydroxyurea—head and neck cancer	0.00287	0.0035	CcSEcCtD
Deferiprone—Pancytopenia—Docetaxel—head and neck cancer	0.00286	0.00349	CcSEcCtD
Deferiprone—Abdominal pain—Vinblastine—head and neck cancer	0.00286	0.00349	CcSEcCtD
Deferiprone—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00285	0.00347	CcSEcCtD
Deferiprone—Fatigue—Hydroxyurea—head and neck cancer	0.00284	0.00347	CcSEcCtD
Deferiprone—Pain—Hydroxyurea—head and neck cancer	0.00282	0.00344	CcSEcCtD
Deferiprone—Neutropenia—Docetaxel—head and neck cancer	0.00282	0.00344	CcSEcCtD
Deferiprone—Weight increased—Docetaxel—head and neck cancer	0.00274	0.00335	CcSEcCtD
Deferiprone—Pneumonia—Docetaxel—head and neck cancer	0.0027	0.0033	CcSEcCtD
Deferiprone—Infestation NOS—Docetaxel—head and neck cancer	0.00269	0.00328	CcSEcCtD
Deferiprone—Infestation—Docetaxel—head and neck cancer	0.00269	0.00328	CcSEcCtD
Deferiprone—Hypersensitivity—Vinblastine—head and neck cancer	0.00266	0.00325	CcSEcCtD
Deferiprone—Jaundice—Docetaxel—head and neck cancer	0.00262	0.0032	CcSEcCtD
Deferiprone—Body temperature increased—Hydroxyurea—head and neck cancer	0.00261	0.00318	CcSEcCtD
Deferiprone—Asthenia—Vinblastine—head and neck cancer	0.0026	0.00317	CcSEcCtD
Deferiprone—Hepatobiliary disease—Docetaxel—head and neck cancer	0.00254	0.0031	CcSEcCtD
Deferiprone—Epistaxis—Docetaxel—head and neck cancer	0.00253	0.00309	CcSEcCtD
Deferiprone—Convulsion—Fluorouracil—head and neck cancer	0.00252	0.00308	CcSEcCtD
Deferiprone—Agranulocytosis—Docetaxel—head and neck cancer	0.00251	0.00306	CcSEcCtD
Deferiprone—Diarrhoea—Vinblastine—head and neck cancer	0.00247	0.00302	CcSEcCtD
Deferiprone—Discomfort—Fluorouracil—head and neck cancer	0.00245	0.00299	CcSEcCtD
Deferiprone—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00243	0.00297	CcSEcCtD
Deferiprone—Hepatitis—Docetaxel—head and neck cancer	0.00241	0.00294	CcSEcCtD
Deferiprone—Pharyngitis—Docetaxel—head and neck cancer	0.00239	0.00292	CcSEcCtD
Deferiprone—Urinary tract disorder—Docetaxel—head and neck cancer	0.00238	0.00291	CcSEcCtD
Deferiprone—Oedema peripheral—Docetaxel—head and neck cancer	0.00238	0.0029	CcSEcCtD
Deferiprone—Anaphylactic shock—Fluorouracil—head and neck cancer	0.00237	0.0029	CcSEcCtD
Deferiprone—Connective tissue disorder—Docetaxel—head and neck cancer	0.00237	0.00289	CcSEcCtD
Deferiprone—Asthenia—Hydroxyurea—head and neck cancer	0.00237	0.00289	CcSEcCtD
Deferiprone—Urethral disorder—Docetaxel—head and neck cancer	0.00236	0.00289	CcSEcCtD
Deferiprone—Infection—Fluorouracil—head and neck cancer	0.00236	0.00288	CcSEcCtD
Deferiprone—Nervous system disorder—Fluorouracil—head and neck cancer	0.00233	0.00284	CcSEcCtD
Deferiprone—Vomiting—Vinblastine—head and neck cancer	0.0023	0.00281	CcSEcCtD
Deferiprone—Headache—Vinblastine—head and neck cancer	0.00227	0.00276	CcSEcCtD
Deferiprone—Diarrhoea—Hydroxyurea—head and neck cancer	0.00226	0.00275	CcSEcCtD
Deferiprone—Eye disorder—Docetaxel—head and neck cancer	0.00225	0.00275	CcSEcCtD
Deferiprone—Cardiac disorder—Docetaxel—head and neck cancer	0.00224	0.00273	CcSEcCtD
Deferiprone—Hypotension—Fluorouracil—head and neck cancer	0.00222	0.00271	CcSEcCtD
Deferiprone—Angiopathy—Docetaxel—head and neck cancer	0.00219	0.00267	CcSEcCtD
Deferiprone—Immune system disorder—Docetaxel—head and neck cancer	0.00218	0.00266	CcSEcCtD
Deferiprone—Mediastinal disorder—Docetaxel—head and neck cancer	0.00217	0.00265	CcSEcCtD
Deferiprone—Chills—Docetaxel—head and neck cancer	0.00216	0.00264	CcSEcCtD
Deferiprone—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00216	0.00264	CcSEcCtD
Deferiprone—Nausea—Vinblastine—head and neck cancer	0.00215	0.00262	CcSEcCtD
Deferiprone—Mental disorder—Docetaxel—head and neck cancer	0.00211	0.00258	CcSEcCtD
Deferiprone—Somnolence—Fluorouracil—head and neck cancer	0.00211	0.00258	CcSEcCtD
Deferiprone—Malnutrition—Docetaxel—head and neck cancer	0.0021	0.00256	CcSEcCtD
Deferiprone—Vomiting—Hydroxyurea—head and neck cancer	0.0021	0.00256	CcSEcCtD
Deferiprone—Dyspepsia—Fluorouracil—head and neck cancer	0.00209	0.00255	CcSEcCtD
Deferiprone—Rash—Hydroxyurea—head and neck cancer	0.00208	0.00254	CcSEcCtD
Deferiprone—Dermatitis—Hydroxyurea—head and neck cancer	0.00208	0.00254	CcSEcCtD
Deferiprone—Headache—Hydroxyurea—head and neck cancer	0.00207	0.00252	CcSEcCtD
Deferiprone—Decreased appetite—Fluorouracil—head and neck cancer	0.00206	0.00252	CcSEcCtD
Deferiprone—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00205	0.0025	CcSEcCtD
Deferiprone—Back pain—Docetaxel—head and neck cancer	0.00203	0.00248	CcSEcCtD
Deferiprone—Pain—Fluorouracil—head and neck cancer	0.00203	0.00248	CcSEcCtD
Deferiprone—Nausea—Hydroxyurea—head and neck cancer	0.00196	0.00239	CcSEcCtD
Deferiprone—Urticaria—Fluorouracil—head and neck cancer	0.00189	0.0023	CcSEcCtD
Deferiprone—Body temperature increased—Fluorouracil—head and neck cancer	0.00188	0.00229	CcSEcCtD
Deferiprone—Convulsion—Docetaxel—head and neck cancer	0.00182	0.00222	CcSEcCtD
Deferiprone—Hypertension—Docetaxel—head and neck cancer	0.00181	0.00221	CcSEcCtD
Deferiprone—Arthralgia—Docetaxel—head and neck cancer	0.00179	0.00218	CcSEcCtD
Deferiprone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00178	0.00217	CcSEcCtD
Deferiprone—Hypersensitivity—Fluorouracil—head and neck cancer	0.00175	0.00213	CcSEcCtD
Deferiprone—Anaphylactic shock—Docetaxel—head and neck cancer	0.00171	0.00209	CcSEcCtD
Deferiprone—Infection—Docetaxel—head and neck cancer	0.0017	0.00208	CcSEcCtD
Deferiprone—Nervous system disorder—Docetaxel—head and neck cancer	0.00168	0.00205	CcSEcCtD
Deferiprone—Pruritus—Fluorouracil—head and neck cancer	0.00168	0.00205	CcSEcCtD
Deferiprone—Skin disorder—Docetaxel—head and neck cancer	0.00166	0.00203	CcSEcCtD
Deferiprone—Diarrhoea—Fluorouracil—head and neck cancer	0.00162	0.00198	CcSEcCtD
Deferiprone—Hypotension—Docetaxel—head and neck cancer	0.0016	0.00195	CcSEcCtD
Deferiprone—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.00156	0.00191	CcSEcCtD
Deferiprone—Somnolence—Docetaxel—head and neck cancer	0.00152	0.00186	CcSEcCtD
Deferiprone—Vomiting—Fluorouracil—head and neck cancer	0.00151	0.00184	CcSEcCtD
Deferiprone—Dyspepsia—Docetaxel—head and neck cancer	0.00151	0.00184	CcSEcCtD
Deferiprone—Rash—Fluorouracil—head and neck cancer	0.0015	0.00183	CcSEcCtD
Deferiprone—Dermatitis—Fluorouracil—head and neck cancer	0.0015	0.00182	CcSEcCtD
Deferiprone—Decreased appetite—Docetaxel—head and neck cancer	0.00149	0.00182	CcSEcCtD
Deferiprone—Headache—Fluorouracil—head and neck cancer	0.00149	0.00181	CcSEcCtD
Deferiprone—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00148	0.00181	CcSEcCtD
Deferiprone—Fatigue—Docetaxel—head and neck cancer	0.00148	0.0018	CcSEcCtD
Deferiprone—Pain—Docetaxel—head and neck cancer	0.00147	0.00179	CcSEcCtD
Deferiprone—Nausea—Fluorouracil—head and neck cancer	0.00141	0.00172	CcSEcCtD
Deferiprone—Gastrointestinal pain—Docetaxel—head and neck cancer	0.0014	0.00171	CcSEcCtD
Deferiprone—Body temperature increased—Docetaxel—head and neck cancer	0.00135	0.00165	CcSEcCtD
Deferiprone—Abdominal pain—Docetaxel—head and neck cancer	0.00135	0.00165	CcSEcCtD
Deferiprone—UGT1A6—Metabolism—NAT2—head and neck cancer	0.0013	0.00723	CbGpPWpGaD
Deferiprone—Hypersensitivity—Docetaxel—head and neck cancer	0.00126	0.00154	CcSEcCtD
Deferiprone—Asthenia—Docetaxel—head and neck cancer	0.00123	0.0015	CcSEcCtD
Deferiprone—Pruritus—Docetaxel—head and neck cancer	0.00121	0.00148	CcSEcCtD
Deferiprone—Diarrhoea—Docetaxel—head and neck cancer	0.00117	0.00143	CcSEcCtD
Deferiprone—UGT1A6—Metabolism—DPYD—head and neck cancer	0.00114	0.00634	CbGpPWpGaD
Deferiprone—Vomiting—Docetaxel—head and neck cancer	0.00109	0.00133	CcSEcCtD
Deferiprone—UGT1A6—Metabolism—YAP1—head and neck cancer	0.00109	0.00602	CbGpPWpGaD
Deferiprone—Rash—Docetaxel—head and neck cancer	0.00108	0.00132	CcSEcCtD
Deferiprone—Dermatitis—Docetaxel—head and neck cancer	0.00108	0.00132	CcSEcCtD
Deferiprone—Headache—Docetaxel—head and neck cancer	0.00107	0.00131	CcSEcCtD
Deferiprone—Nausea—Docetaxel—head and neck cancer	0.00102	0.00124	CcSEcCtD
Deferiprone—UGT1A6—Metabolism—TYMS—head and neck cancer	0.000652	0.00361	CbGpPWpGaD
Deferiprone—UGT1A6—Metabolism—GSTM1—head and neck cancer	0.000644	0.00357	CbGpPWpGaD
Deferiprone—UGT1A6—Metabolism—GPX1—head and neck cancer	0.000617	0.00342	CbGpPWpGaD
Deferiprone—UGT1A6—Metabolism—CYP1A1—head and neck cancer	0.000611	0.00339	CbGpPWpGaD
Deferiprone—UGT1A6—Metabolism—PTGS2—head and neck cancer	0.000363	0.00201	CbGpPWpGaD
Deferiprone—UGT1A6—Metabolism—PTEN—head and neck cancer	0.000317	0.00176	CbGpPWpGaD
Deferiprone—UGT1A6—Metabolism—PIK3CA—head and neck cancer	0.000223	0.00124	CbGpPWpGaD
Deferiprone—UGT1A6—Metabolism—AKT1—head and neck cancer	0.000183	0.00101	CbGpPWpGaD
